ArticleScience advances2020
A novel mouse model of chronic suppurative otitis media and its use in preclinical antibiotic evaluation.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Challenges in functional hydrogel application for chronic tympanic membrane perforation: practical limitations and lessons learned.Biomedical engineering letters · 2026Article
- Identification and mechanism of key genes in inflammatory response of chronic otitis media in rats.Scientific reports · 2025Article
- Management Strategies for Chronic Suppurative Otitis Media and Why They Fail.Journal of the Association for Research in Otolaryngology : JARO · 2025Review
- Causal relationship between gastroesophageal reflux disease and the risk of chronic suppurative otitis media: a mendelian randomization analysis.SAGE open medicine · 2025Article
- A Selection Protocol to Identify Therapeutics to Target NLRP3-Associated Sensory Hearing Loss.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2024Article
- Targeting the NLRP3 inflammasome in cochlear macrophages protects against hearing loss in chronic suppurative otitis media.Journal of neuroinflammation · 2024Article
- Chemokine Receptor CCR2 Is Protective toward Outer Hair Cells in Chronic Suppurative Otitis Media.ImmunoHorizons · 2024Article
- Article
- Overcoming barriers: a review on innovations in drug delivery to the middle and inner ear.Frontiers in pharmacology · 2023Review
- Endoscope-assisted magnetic helical micromachine delivery for biofilm eradication in tympanostomy tube.Science advances · 2022Article
- Chronic suppurative otitis media causes macrophage-associated sensorineural hearing loss.Journal of neuroinflammation · 2022Article
- Gold nanocluster adjuvant enables the eradication of persister cells by antibiotics and abolishes the emergence of resistance.Nanoscale · 2022Article
- Article
- Antibiofilm activity of host defence peptides: complexity provides opportunities.Nature reviews. Microbiology · 2021Review
- Treatment with a neutrophil elastase inhibitor and ofloxacin reduces P. aeruginosa burden in a mouse model of chronic suppurative otitis media.NPJ biofilms and microbiomes · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic suppurative otitis media (CSOM) is a neglected pediatric disease affecting 330 million worldwide for which no new drugs have been introduced for over a decade. We developed a mouse model with utility in preclinical drug evaluation and antimicrobial discovery. Our model used immune-competent mice, tympanic membrane perforation and inoculation with luminescent Pseudomonas aeruginosa that enabled bacterial abundance tracking in real-time for 100 days. The resulting chronic infection exhibited hallmark features of clinical CSOM, including inhibition of tympanic membrane healing and purulent ear discharge. We evaluated the standard care fluoroquinolone ofloxacin and demonstrated that this therapy resulted in a temporary reduction of bacterial burden. These data are consistent with the clinical problem of persistent infection in CSOM and the need for therapeutic outcome measures that assess eradication post-therapeutic endpoint. We conclude that this novel mouse model of CSOM has value in investigating new potential therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.